Diaceutics PLC (LON:DXRX – Get Free Report) insider Jordan Clark sold 250,000 shares of the company’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of GBX 190, for a total value of £475,000.
Diaceutics Price Performance
DXRX stock traded down GBX 1 during mid-day trading on Friday, hitting GBX 194. The stock had a trading volume of 330,586 shares, compared to its average volume of 298,740. The company has a current ratio of 2.55, a quick ratio of 9.92 and a debt-to-equity ratio of 5.40. The firm has a market capitalization of £164.85 million, a P/E ratio of -606.25 and a beta of 0.88. The firm has a fifty day simple moving average of GBX 188.20 and a 200 day simple moving average of GBX 160.85. Diaceutics PLC has a 52 week low of GBX 125 and a 52 week high of GBX 210.
Diaceutics (LON:DXRX – Get Free Report) last announced its quarterly earnings data on Tuesday, September 22nd. The company reported GBX (3.27) EPS for the quarter. Diaceutics had a negative net margin of 0.66% and a negative return on equity of 0.68%. As a group, research analysts forecast that Diaceutics PLC will post 1.01 EPS for the current year.
Analysts Set New Price Targets
Check Out Our Latest Research Report on Diaceutics
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.
Read More
- Five stocks we like better than Diaceutics
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
- Firefly Aerospace Lights Up a High-Risk Space Opportunity
- Is Buying the NVIDIA Dip a Mistake? 3 Value Stocks Offer a Different Path Forward
Receive News & Ratings for Diaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diaceutics and related companies with MarketBeat.com's FREE daily email newsletter.
